Publications by authors named "Philippe Moris"

Claim this Profile
S
Safety and Immunogenicity of OVX836, a Nucleoprotein-Based Universal Influenza Vaccine, Co-Administered with Fluarix Tetra, a Seasonal Hemagglutinin-Based Vaccine.
Nicola Groth, Jacques Bruhwyler, Jessika Tourneur, Emilie Piat, Philippe Moris

Vaccines (Basel)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Safety, Immunogenicity and Cross-Reactive Immunity of OVX836, a Nucleoprotein-Based Universal Influenza Vaccine, in Older Adults.
Bart Jacobs, Isabel Leroux-Roels, Jacques Bruhwyler, Nicola Groth, Gwenn Waerlop, Philippe Moris

Vaccines (Basel)· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12-23 Months of Age.
Javier Díez-Domingo, Xavier Sáez-Llorens, Miguel A Rodriguez-Weber, Cristina Epalza, Archana Chatterjee, Philippe Moris

J Infect Dis· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of B-cell and T-cell responses to a tetravalent dengue purified inactivated vaccine in healthy adults.
Heather Friberg, Morgan Gargulak, Amanda Kong, Leyi Lin, Luis J Martinez, Philippe Moris

NPJ Vaccines· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine.
Isabel Leroux-Roels, Gwenn Waerlop, Jessika Tourneur, Fien De Boever, Catherine Maes, Philippe Moris

Front Immunol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Whole blood can be used as an alternative to isolated peripheral blood mononuclear cells to measure in vitro specific T-cell responses in human samples.
Philippe Moris, Aurélie Bellanger, Opokua Ofori-Anyinam, Erik Jongert, Juan-Pablo Yarzabal Rodriguez

J Immunol Methods· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of an AS03-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized Study.
Leyi Lin, Kirsten E Lyke, Michael Koren, Richard G Jarman, Kenneth H Eckels, Philippe Moris

Am J Trop Med Hyg· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults.
Paola Cicconi, Claire Jones, Esha Sarkar, Laura Silva-Reyes, Paul Klenerman, Philippe Moris

Clin Infect Dis· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions.
Philippe Moris, Kristen M Bauer, Jeffrey R Currier, Heather Friberg, Kenneth H Eckels

Hum Vaccin Immunother· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-typeable Haemophilus influenzae protein vaccine in adults with COPD: A phase 2 clinical trial.
Tom M A Wilkinson, Stuart Schembri, Christopher Brightling, Nawar D Bakerly, Keir Lewis, Philippe Moris

Vaccine· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine.
Nicolas Folschweiller, Ulrich Behre, Marc Dionne, Paolo Durando, Susanna Esposito, Philippe Moris

J Infect Dis· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of T-cell immune responses in clinical trials of the candidate RTS,S malaria vaccine.
Philippe Moris, Erik Jongert, Robbert G van der Most

Hum Vaccin Immunother· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study.
Paul Gillard, Pan-Chyr Yang, Manfred Danilovits, Wei-Juin Su, Shih-Lung Cheng, Philippe Moris

Tuberculosis (Edinb)· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial.
Geert Leroux-Roels, Arnaud Marchant, Jack Levy, Pierre Van Damme, Tino F Schwarz, Philippe Moris

Clin Immunol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies.
José Garcia-Sicilia, Javier Arístegui, Félix Omeñaca, Alfonso Carmona, Juan C Tejedor, Philippe Moris

Hum Vaccin Immunother· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine and Evaluation of a Booster Dose Administered to Healthy Thai Children.
Veerachai Watanaveeradej, Sriluck Simasathien, Mammen P Mammen, Ananda Nisalak, Elodie Tournay, Philippe Moris

Am J Trop Med Hyg· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Ad35.CS.01-RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults.
Christian F Ockenhouse, Jason Regules, Donna Tosh, Jessica Cowden, April Kathcart, Philippe Moris

PLoS One· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Controlled Safety, and Immunogenicity Trial of the M72/AS01 Candidate Tuberculosis Vaccine in HIV-Positive Indian Adults.
Nagalingeswaran Kumarasamy, Selvamuthu Poongulali, Anne Bollaerts, Philippe Moris, Faith Esther Beulah

Medicine (Baltimore)· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial.
Jack Levy, Laurent Licini, Edwige Haelterman, Philippe Moris, Pascal Lestrate

Hum Vaccin Immunother· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study.
Mark H Einstein, Myron J Levin, Archana Chatterjee, Nahida Chakhtoura, Peter Takacs, Philippe Moris

Hum Vaccin Immunother· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naïve adults.
Geert Leroux-Roels, Isabel Leroux-Roels, Frédéric Clement, Opokua Ofori-Anyinam, Marc Lievens, Philippe Moris

Hum Vaccin Immunother· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting.
Adam Penn-Nicholson, Hennie Geldenhuys, Wivine Burny, Robbert van der Most, Cheryl L Day, Philippe Moris

Vaccine· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination.
Javier Díez-Domingo, José-María Baldó, Maria Victoria Planelles-Catarino, María Garcés-Sánchez, Isabel Ubeda, Philippe Moris

Influenza Other Respir Viruses· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: a randomized controlled clinical trial.
Joanne M Langley, Louise Frenette, Robert Jeanfreau, Scott A Halperin, Michael Kyle, Philippe Moris

Vaccine· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial.
Olubukola T Idoko, Olumuyiwa A Owolabi, Patrick K Owiafe, Philippe Moris, Aderonke Odutola

Tuberculosis (Edinb)· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis